Peer-Spectives Podcasts
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Acute myeloid leukemia (AML) and Acute lymphocytic leukemia (ALL) – David Sallman, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2020
Tuesday December 22, 2020
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center discuss CAR T as it pertains to clinical advances in leukemia
Bladder Cancer – Robert Figlin, MD, and Arjun Balar, MD, discuss clinical progress in bladder cancer
Sunday February 28, 2021
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Arjun Balar, MD, Director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discuss clinical progress in bladder cancer
Monday February 22, 2021
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Neeraj Agarwal, MD, Professor of Medicine, Huntsman Cancer Institute, Presidential Endowed Chair of Cancer Research , Co-Leader, HCI Experimental Therapeutics Program, Director, Center of Investigational Therapeutics, Director, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, discuss clinical progress in prostate cancer
Monday February 22, 2021
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss clinical progress in renal cell carcinoma (RCC)
Tuesday January 12, 2021
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Adam Brufsky, MD, PhD, Professor of Medicine, Associate Division Chief for the Division of Hematology/Oncology, UPMC, discuss clinical highlights from SABCS 2020
Monday January 11, 2021
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Mazyar Shadman, MD, MPH, Associate Professor, Clinical Research Division Fred Hutchinson Cancer Research Center, discuss clinical highlights in the treatment of CLL from ASH 2020
Monday October 26, 2020
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley McGregor, MD, Clinical Director, Lank Center for Genitourinary Oncology, Professor of Medicine, Harvard Medical School, discuss Checkmate 9ER and other I-O studies as they pertain to the management of RCC patients
Wednesday October 21, 2020
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Victoria Villaflor, MD, Clinical Professor, Director Head and Neck Oncology at City of Hope, discuss unresectable stage III Non Small Cell Lung Cancer (www.azioinpractice.com)
Friday October 16, 2020
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Geoffrey Ku, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discuss recent clinical developments in gastric and esophageal cancer
Friday July 17, 2020
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Sara Hurvitz, MD, Associate Professor of Medicine, Geffen School of Medicine, UCLA, Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit, discuss breast cancer patient types, challenges, and treatment advances.
Thursday June 25, 2020
Roy Herbst, MD, and Robert Figlin, MD, discuss the implications of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patients
Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021
Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer
Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers
Follow @OBRTweets